BMRN BioMarin Pharmaceutical Inc. - Common Stock
$67,68
Precio · Ago 18, 2026
Fundamentales a fecha de Ago 6, 2026
Rango 52S
$49–$71
85% of range
Calificación del Analista
BUY
33 analysts
Precio Objetivo
$90
+33% upside
P/E (TTM)
37.8
ROE
5.8%
Margen de Beneficio Neto
10.8%
Acerca de BioMarin Pharmaceutical Inc. - Common Stock Descripción general de la empresa de Wikipedia
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Leer más
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
History
BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.
Business development
In 2002, BioMarin acquired Glyko Biomedical.
In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert–Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse.
In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia.
In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
In 2014, BioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for $2 million with the intention of advancing work toward therapies for Friedreich's ataxia and other neurological disorders.
In November 2014, the company agreed to the acquisition of Prosensa for up to $840 million; however, the range of treatments for Duchenne muscular dystrophy failed to attain FDA approval, and development ceased in May 2016.
In October 2019 it was revealed that the group will open an office in Dublin to support further growth through Europe, the Middle East and Asia.
In December 2025, BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion.
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Products
As of 2022, BioMarin has six products on the market, each of which is an orphan drug.
Tetrahydrobiopterin (branded as Kuvan) (sapropterin dihydrochloride), a small molecule drug for phenylketonuria, introduced in 2007 as the first medication-based intervention to treat phenylketonuria
Arylsulfatase B (branded as Naglazyme) (galsulfase), a recombinant protein therapeutic for Maroteaux–Lamy syndrome (also called mucopolysaccharidosis type VI)
Iduronidase (branded as Aldurazyme), a recombinant protein therapeutic for mucopolysaccharidosis I
Amifampridine (branded as Firdapse), a small molecule drug for Lambert–Eaton myasthenic syndrome (as of 2013 approved in the EU only)
Elosulfase alfa (branded as Vimizim), is the only enzyme replacement therapy to address the cause of Morquio A Syndrome (MPS IVA), which affects an estimated 3,000 patients in the developed world. The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan (GAG) metabolism.
Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017.
Valoctocogene roxaparvovec (branded as Roctavian) is an adeno-associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one. It was approved in the EU in August 2022.
Biomarin is working to develop several new drugs.
Controversies
In 2010, BioMarin became involved in controversy surrounding 3,4-diaminopyridine (3,4-DAP). BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its licensing, there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process.
In 2013, BioMarin Pharmaceuticals was at the center of a high-profile debate regarding expanded access of cancer patients to experimental drugs. On the advice of her doctor, Andrea Sloan, a patient with advanced ovarian cancer, requested that the company provide her with access to BMN 673, an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase 1 clinical trial. The company declined, citing safety concerns. Ms. Sloan eventually received a similar drug candidate from a different company.
In 2015, there was another controversy over expanded access, concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial.
In April 2019, the BBC reported that patients who took part in a trial treatment for the drug Kuvan (sapropterin hydrochloride) were later denied access to it. The company was criticised by the NHS and Stephen Hammond MP for patient profiteering. The company commented the following in response: "BioMarin is disappointed that the NHS England has not recognised the value of treating PKU patients with Kuvan, despite more than a decade of positive patient outcomes across 26 countries in Europe, Russia and Turkey"
In June 2019, a Belgian court ordered BioMarin to continue supplying Vimizim to a young girl suffering from Morquio syndrome free of charge. BioMarin stopped providing free Vimizim at the beginning of the year after negotiations with Belgian health authorities regarding reimbursement of the product repeatedly failed. This caused the parents to start legal proceedings to force the company to keep providing the medicine free of charge. BioMarin was ordered in a preliminary injunction to keep doing so until a definitive judgment would be rendered, or until the medicine would be available on the Belgian market at a reasonable price.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
BMRN Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$67.68
Capitalización Bursátil
$13.08B
P/E (TTM)
37.8
BPA (TTM)
$1.80
Ingresos (TTM)
$3.22B
Rendimiento div.
—
ROE
5.8%
Deuda/Capital
—
Rango 52S
$49 – $71
BMRN Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$3.22B
2016-12-31
→
2025-12-31
BPA
$1.80
2016-12-31
→
2025-12-31
Flujo de caja libre
$725M
2016-12-31
→
2025-12-31
Márgenes
10.8%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
BMRN
Mediana de Pares
P/E (TTM)
37.8
28.5
P/S (TTM) (P/V (TTM))
4.1
20.1
P/B (P/C)
2.1
12.9
Price / FCF (Precio / FCF)
18.0
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
BMRN
Mediana de Pares
Operating Margin (Margen Operativo)
12.7%
—
Net Profit Margin (Margen de Beneficio Neto)
10.8%
-48.4%
ROA
4.8%
-28.4%
ROE
5.8%
-49.2%
ROIC
4.9%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
BMRN
Mediana de Pares
Current Ratio (Ratio corriente)
5.2
5.0
Quick Ratio (Ratio Rápido)
2.9
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
BMRN
Mediana de Pares
Revenue YoY (Ingresos interanuales)
12.9%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
15.4%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
11.6%
—
EPS YoY (EPS interanual)
-18.6%
—
Net Income YoY (Beneficio Neto interanual)
-18.3%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
BMRN
Mediana de Pares
BMRN Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
33 analistas
- Compra fuerte 10 30,3%
- Compra 16 48,5%
- Mantener 7 21,2%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
25 analistas · 2026-08-14
Mediana
$86.00
Ahora
$67.68
Mín
$60.00
Máx
$124.00
Objetivo mediano
$86.00
+27,1%
Objetivo medio
$90.32
+33,5%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-0.17%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $0.73 | $0.70 | 0.03% |
| 31 de marzo de 2026 | $0.54 | $0.77 | -0.23% |
| 31 de diciembre de 2025 | $-0.24 | $0.64 | -0.88% |
| 30 de septiembre de 2025 | $-0.16 | $0.38 | -0.54% |
| 30 de junio de 2025 | $1.23 | $0.85 | 0.38% |
| 31 de marzo de 2025 | $0.95 | $0.72 | 0.23% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Cost of Revenue | $717M | $580M | $532M | $503M | $471M | $524M | $359M | $315M | $242M | $210M | $152M | $122M | |
| R&D Expense | $922M | $747M | $747M | $650M | $629M | $628M | $715M | $696M | $611M | $662M | $635M | $462M | |
| SG&A Expense | $1.15B | $1.01B | $892M | $823M | $759M | $738M | $681M | $604M | $554M | $477M | $402M | $302M | |
| Operating Expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B | $1.33B | $1.92B | $1.00B | $842M | |
| Operating Income | $409M | $484M | $186M | $161M | $-82M | $-43M | $-100M | $-124M | $-15M | $-803M | $-111M | $-93M | |
| Interest Expense | · | · | $17M | $16M | $15M | $29M | $23M | $44M | $43M | $39M | $38M | $37M | |
| Interest Income | $75M | $75M | $58M | $18M | $10M | $17M | $23M | $23M | $15M | $7M | $5M | $6M | |
| Pretax Income | $482M | $542M | $189M | $150M | $-75M | $-49M | $-95M | $-143M | $-36M | $-831M | $-155M | $-125M | |
| Income Tax | $134M | $115M | $21M | $8M | $-11M | $-903M | $-71M | $-65M | $81M | $-201M | $17M | $9M | |
| Net Income | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 | $-1.07 | $-0.92 | |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 | |
| Shares (Basic) | 191,787,000 | 190,027,000 | 187,834,000 | 185,266,000 | 182,852,000 | 180,804,000 | 179,039,000 | 177,061,000 | 174,427,000 | 165,985,000 | 160,025,000 | 146,349,000 | |
| Shares (Diluted) | 197,394,000 | 196,708,000 | 191,595,000 | 188,963,000 | 182,852,000 | 191,678,000 | 179,039,000 | 177,268,000 | 174,427,000 | 166,219,000 | 160,025,000 | 146,349,000 | |
| EBITDA | $489M | $581M | $262M | $252M | $26M | $68M | $5M | $-28M | $73M | $-707M | $-64M | $-93M |
Balance general 28
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.31B | $943M | $755M | $725M | $587M | $649M | $437M | $494M | $598M | $408M | $397M | $875M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $798M | $381M | $196M | $70M | |
| Receivables | $908M | $661M | $634M | $461M | $373M | $448M | $377M | $343M | $261M | $215M | $165M | $144M | |
| Inventory | $1.30B | $1.23B | $1.11B | $894M | $777M | $699M | $680M | $531M | $476M | $355M | $272M | $199M | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | · | $28M | $35M | |
| Other Current Assets | $186M | $202M | $141M | $105M | $110M | $130M | $131M | $98M | $74M | $62M | $60M | $109M | |
| Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B | $2.21B | $1.42B | $1.09B | $1.40B | |
| PP&E (Net) | $953M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $949M | $897M | $799M | $704M | $524M | |
| PP&E (Gross) | $2.03B | $1.93B | $1.93B | $1.88B | $1.76B | $1.67B | $1.56B | $1.42B | $1.30B | $1.14B | $983M | $752M | |
| Accum. Depreciation | $1.07B | $892M | $867M | $802M | $721M | $636M | $549M | $473M | $407M | $343M | $279M | $229M | |
| Goodwill | $196M | $196M | $196M | $196M | $196M | $196M | $197M | $197M | $197M | $197M | $197M | $54M | |
| Intangibles | $214M | $255M | $295M | $339M | $389M | $417M | $457M | $492M | $518M | $554M | $684M | $157M | |
| Other Non-current Assets | $277M | $251M | $172M | $176M | $152M | $142M | $122M | $37M | $30M | $33M | $409M | $55M | |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Accounts Payable | $759M | $607M | $683M | $573M | $498M | $493M | $571M | $437M | $402M | $371M | $393M | $232M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $98M | |
| Current Liabilities | $759M | $607M | $1.18B | $589M | $546M | $493M | $933M | $523M | $817M | $439M | $445M | $236M | |
| Capital Leases | $37M | $31M | $38M | $26M | $32M | $40M | $44M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $144M | · | |
| Other Non-current Liabilities | $151M | $129M | $120M | $100M | $98M | $114M | $98M | $59M | $59M | $42M | $45M | $30M | |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B | $1.33B | $947M | |
| Long-term Debt | $597M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $192.0K | $191.0K | $189.0K | $186.0K | $184.0K | $182.0K | $180.0K | $178.0K | $176.0K | $173.0K | $162.0K | $149.0K | |
| Retained Earnings | $154M | $-195M | $-622M | $-789M | $-931M | $-862M | $-1.72B | $-1.69B | $-1.64B | $-1.52B | $-1.02B | $-850M | |
| AOCI | $-13M | $62M | $-29M | $-4M | $14M | $-16M | $20M | $5M | $-23M | $13M | $21M | $27M | |
| Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B | $2.81B | $2.77B | $2.40B | $1.53B | |
| Liabilities + Equity | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Shares Outstanding | 192,300,101 | 190,761,000 | 188,598,000 | 186,251,000 | 183,913,000 | 181,741,000 | 179,838,000 | 178,252,954 | 175,843,749 | 172,647,588 | 161,526,044 | 149,093,647 |
Flujo de Efectivo 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $80M | $96M | $104M | $102M | $108M | $105M | $105M | $96M | $88M | $97M | $47M | $46M | |
| Stock-based Comp | $181M | $202M | $207M | $196M | $197M | $190M | $160M | $149M | $140M | $135M | $112M | $86M | |
| Deferred Tax | $49M | $56M | $-45M | $-52M | $-16M | $-890M | $-83M | $-68M | $44M | $-228M | $-77M | $-26M | |
| Amort. of Intangibles | $19M | $43M | $62M | $67M | · | · | · | · | · | · | · | $10M | |
| Other Non-cash | $169M | $-208M | $-275M | $-212M | $79M | $-180M | $-110M | $-79M | $-164M | $399M | $-132M | · | |
| Operating Cash Flow | $828M | $573M | $159M | $176M | $305M | $85M | $48M | $20M | $-9M | $-228M | $-219M | $-70M | |
| CapEx | $103M | $85M | $97M | $121M | $96M | $114M | $145M | $145M | $199M | $148M | $228M | $117M | |
| Investing Cash Flow | $-414M | $136M | $-111M | $-20M | $-366M | $-54M | $-31M | $264M | $-305M | $-484M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $713M | $888M | $117M | |
| Stock Repurchased | · | · | · | $0 | $0 | $50M | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | · | · | $0 | $0 | $-50M | · | $0 | $0 | $713M | $888M | $117M | |
| Financing Cash Flow | $-42M | $-526M | $-19M | $-19M | $-48.0K | $181M | $-75M | $-388M | $507M | $727M | · | · | |
| Net Change in Cash | $369M | $188M | $31M | $137M | $-62M | $212M | $-57M | $-104M | $190M | $11M | $-478M | $307M | |
| Taxes Paid | $96M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $725M | $487M | $63M | $55M | $209M | $-29M | $-97M | $-124M | $-208M | $-376M | $-449M | $-192M | |
| Levered FCF | · | · | $47M | $40M | $196M | $566M | $-103M | $-148M | $-347M | $-406M | $-492M | $-232M |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% | -2.0% | -5.9% | -8.3% | -1.1% | -71.9% | -12.4% | -12.4% | |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 46.2% | -1.4% | -5.2% | -8.9% | -56.4% | -19.3% | -17.8% | |
| Pretax Margin | 15.0% | 19.0% | 7.8% | 7.1% | -4.1% | -2.3% | -5.6% | -9.6% | -2.7% | -74.4% | -17.4% | -16.6% | |
| EBITDA Margin | 15.2% | 20.3% | 10.8% | 12.0% | 1.4% | 3.7% | 0.28% | -1.9% | 5.6% | -63.3% | -7.1% | -12.4% | |
| ROA | 4.8% | 6.2% | 2.5% | 2.3% | -1.1% | 16.3% | -0.52% | -1.7% | -2.7% | -16.3% | -5.5% | -5.7% | |
| ROE | 5.8% | 7.7% | 3.4% | 3.1% | -1.5% | 21.1% | -0.77% | -2.6% | -4.2% | -24.4% | -8.8% | -9.3% | |
| ROIC | 4.9% | 6.7% | 2.8% | 3.1% | -1.6% | 18.2% | -0.81% | -2.2% | -1.7% | -22.0% | -5.1% | -6.5% |
Liquidez y Solvencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 | 4.8 | 2.1 | 3.9 | 2.7 | 3.2 | 2.4 | 6.0 | |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 | 2.2 | 0.9 | 1.6 | 2.0 | 2.3 | 1.7 | 4.6 | |
| Interest Coverage | · | · | 9.1 | 9.4 | -5.4 | -1.3 | -4.3 | -2.8 | -0.3 | -20.3 | -2.9 | -2.5 |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Inventory Turnover | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.6 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.5 | 4.5 | 4.7 | 4.9 | 5.5 | 5.9 | 5.8 | 5.7 |
Tasas de Crecimiento 9
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 12.9% | 18.0% | 15.4% | 13.5% | -0.76% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 15.4% | 15.6% | 9.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -18.6% | 154.0% | 16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 33.9% | · | -42.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -16.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -18.3% | 154.6% | 18.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 35.1% | · | -41.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -16.4% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 10
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Net Income TTM | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| Market Cap | $11.43B | $12.54B | $18.18B | $19.28B | $16.25B | $15.94B | $15.21B | $15.18B | $15.68B | $14.30B | $16.92B | $13.48B | |
| P/E | 33.0 | 29.7 | 110.8 | 138.0 | -252.4 | 19.5 | -650.4 | -193.5 | -133.1 | -21.7 | -97.9 | -98.3 | |
| P/S | 3.5 | 4.4 | 7.5 | 9.2 | 8.8 | 8.6 | 8.9 | 10.2 | 11.9 | 12.8 | 19.0 | 18.0 | |
| P/B | 1.9 | 2.2 | 3.7 | 4.2 | 3.8 | 3.9 | 4.9 | 5.1 | 5.6 | 5.2 | 7.0 | 8.8 | |
| P / Tangible Book | 2.0 | 2.4 | 4.1 | 4.7 | 4.4 | 4.6 | · | · | · | · | · | · | |
| P / Cash Flow | 13.8 | 21.9 | 114.2 | 109.6 | 53.4 | 186.7 | 315.1 | 751.1 | -1790.6 | -62.8 | -76.3 | -183.3 | |
| P / FCF | 15.8 | 25.7 | 290.6 | 350.8 | 77.8 | -550.6 | -157.1 | -122.0 | -75.4 | -38.0 | -37.7 | -70.1 | |
| Earnings Yield | 3.0% | 3.4% | 0.90% | 0.72% | -0.40% | 5.1% | -0.15% | -0.52% | -0.75% | -4.6% | -1.0% | -1.0% |
Estado de resultados 16
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $990M | $766M | $875M | $776M | $825M | $745M | $747M | $746M | $712M | $649M | $646M | $581M | $595M | $596M | $538M | $505M | |
| Cost of Revenue | $203M | $195M | $276M | $140M | $150M | $152M | $136M | $188M | $130M | $125M | $138M | $128M | $131M | $135M | $147M | $116M | |
| R&D Expense | $207M | $179M | $192M | $409M | $161M | $159M | $174M | $185M | $184M | $205M | $206M | $191M | $177M | $172M | $173M | $158M | |
| SG&A Expense | $396M | $258M | $446M | $268M | $232M | $206M | $267M | $253M | $263M | $226M | $260M | $216M | $206M | $211M | $215M | $217M | |
| Operating Expenses | $879M | $637M | $919M | $823M | $549M | $521M | $586M | $632M | $592M | $560M | $619M | $551M | $530M | $534M | $551M | $508M | |
| Operating Income | $111M | $130M | $-45M | $-47M | $277M | $224M | $161M | $114M | $120M | $88M | $27M | $31M | $66M | $62M | $-13M | $-2M | |
| Interest Expense | $61M | $10M | · | · | $2M | $2M | · | · | · | $4M | · | $4M | $4M | $4M | · | $5M | |
| Interest Income | $10M | $23M | $19M | $18M | $19M | $19M | $18M | $18M | $20M | $19M | $18M | $16M | $13M | $12M | $9M | $5M | |
| Pretax Income | $61M | $141M | $-27M | $-26M | $298M | $238M | $170M | $134M | $132M | $106M | $19M | $42M | $71M | $57M | $-18M | $-2M | |
| Income Tax | $17M | $36M | $19M | $4M | $57M | $52M | $45M | $28M | $25M | $17M | $-1M | $1M | $15M | $6M | $-17M | $5M | |
| Net Income | $45M | $106M | $-47M | $-31M | $241M | $186M | $125M | $106M | $107M | $89M | $20M | $40M | $56M | $51M | $-249.0K | $-7M | |
| EPS (Basic) | $0.23 | $0.55 | $-0.24 | $-0.16 | $1.25 | $0.97 | $0.66 | $0.56 | $0.56 | $0.47 | $0.11 | $0.21 | $0.30 | $0.27 | $-0.01 | $-0.04 | |
| EPS (Diluted) | $0.23 | $0.54 | $-0.22 | $-0.16 | $1.23 | $0.95 | $0.65 | $0.55 | $0.55 | $0.46 | $0.10 | $0.21 | $0.29 | $0.27 | $0.01 | $-0.04 | |
| Shares (Basic) | 193,423,000 | 192,497,000 | -383,119,000 | 192,032,000 | 191,907,000 | 190,967,000 | -379,382,000 | 190,429,000 | 190,114,000 | 188,866,000 | -375,000,000 | 188,219,000 | 187,948,000 | 186,667,000 | -369,575,000 | 185,597,000 | |
| Shares (Diluted) | 194,467,000 | 197,671,000 | -388,203,000 | 192,032,000 | 197,091,000 | 196,474,000 | -400,206,000 | 197,147,000 | 200,505,000 | 199,262,000 | -388,939,000 | 191,173,000 | 194,998,000 | 194,363,000 | -378,968,000 | 185,597,000 | |
| EBITDA | $111M | $146M | · | $-47M | $277M | $246M | · | $114M | $120M | $116M | · | $26M | $59M | $86M | · | $-2M |
Balance general 25
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $874M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $943M | $675M | $972M | $747M | · | $785M | $694M | $580M | · | $762M | |
| Receivables | $1.06B | $904M | $908M | $790M | $856M | $739M | $661M | $778M | $691M | $637M | · | $572M | $610M | $598M | · | $420M | |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | · | $1.03B | $976M | $919M | · | $839M | |
| Other Current Assets | $254M | $206M | $186M | $204M | $177M | $182M | $202M | $169M | $160M | $163M | · | $225M | $193M | $173M | · | $150M | |
| Current Assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | · | $2.96B | $2.95B | $2.84B | · | $2.68B | |
| PP&E (Net) | $990M | $958M | $953M | $1.04B | $1.03B | $1.03B | $1.04B | $1.05B | $1.05B | $1.06B | · | $1.07B | $1.07B | $1.07B | · | $1.05B | |
| PP&E (Gross) | $2.10B | $2.05B | $2.03B | $1.99B | $1.96B | $1.94B | $1.93B | $1.91B | $1.96B | $1.95B | · | $1.92B | $1.90B | $1.88B | · | $1.83B | |
| Accum. Depreciation | $1.11B | $1.09B | $1.07B | $950M | $931M | $908M | $892M | $869M | $910M | $888M | · | $851M | $829M | $807M | · | $782M | |
| Goodwill | $656M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | · | $196M | $196M | $196M | · | $196M | |
| Intangibles | $4.88B | $205M | $214M | $233M | $240M | $247M | $255M | $261M | $266M | $280M | · | $302M | $310M | $326M | · | $354M | |
| Other Non-current Assets | $338M | $276M | $277M | $271M | $249M | $236M | $251M | $199M | $191M | $185M | · | $165M | $144M | $150M | · | $152M | |
| Total Assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Accounts Payable | $1.01B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $572M | $594M | · | $670M | $597M | $598M | · | $493M | |
| Current Liabilities | $1.66B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $1.07B | $1.09B | · | $1.16B | $597M | $598M | · | $521M | |
| Capital Leases | · | · | $37M | · | · | · | $31M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $210M | $155M | $151M | $163M | $149M | $130M | $129M | $128M | $119M | $117M | · | $105M | $98M | $92M | · | $92M | |
| Total Liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | · | $1.86B | $1.78B | $1.77B | · | $1.70B | |
| Long-term Debt | $4.19B | $1.43B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $4.19B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $194.0K | $193.0K | $192.0K | $192.0K | $192.0K | $192.0K | $191.0K | $191.0K | $190.0K | $190.0K | · | $188.0K | $188.0K | $188.0K | · | $186.0K | |
| Retained Earnings | $304M | $260M | $154M | $201M | $232M | $-9M | $-195M | $-320M | $-426M | $-533M | · | $-642M | $-682M | $-738M | · | $-789M | |
| AOCI | $-9M | $-4M | $-13M | $-34M | $-45M | $19M | $62M | $5M | $27M | $-1M | · | $6M | $-19M | $-11M | · | $31M | |
| Stockholders' Equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B | $4.90B | $4.78B | $4.66B | $4.60B | $4.57B | |
| Liabilities + Equity | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Shares Outstanding | 193,535,556 | 193,268,870 | 192,300,101 | 192,098,751 | 192,001,650 | 191,755,802 | 190,761,349 | 190,553,918 | 190,355,517 | 189,776,577 | 188,598,000 | 188,339,482 | 188,151,695 | 187,601,106 | 186,251,000 | 185,824,253 |
Flujo de Efectivo 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $98M | $16M | $20M | $18M | $19M | $22M | $24M | $19M | $26M | $27M | $27M | $26M | $25M | $26M | $25M | $25M | |
| Stock-based Comp | $76M | $43M | $47M | $49M | $48M | $38M | $52M | $43M | $48M | $58M | $55M | $48M | $50M | $54M | $47M | $55M | |
| Deferred Tax | $-7M | $9M | $613.0K | $-14M | $33M | $28M | $42M | $12M | $1M | $285.0K | $-25M | $-15M | $1M | $-6M | $-51M | $-4M | |
| Amort. of Intangibles | $73M | $4M | $5M | $5M | $5M | $5M | $10M | $5M | $14M | $14M | $15M | $16M | $16M | $16M | · | · | |
| Restructuring | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $46M | · | · | · | $-99M | · | · | · | $-128M | · | · | · | $-199M | · | · | |
| Operating Cash Flow | $168M | $221M | $100M | $369M | $185M | $174M | $186M | $221M | $119M | $47M | $27M | $136M | $70M | $-74M | $7M | $158M | |
| CapEx | $29M | $21M | $41M | $28M | $17M | $17M | $20M | $18M | $21M | $26M | $29M | $22M | $22M | $24M | $36M | $29M | |
| Investing Cash Flow | $-5.10B | $726M | $-42M | $-331M | $-13M | $-28M | $76M | $-16M | $90M | $-14M | $-65M | $-46M | $30M | $-30M | $-55M | $-23M | |
| Financing Cash Flow | $2.74B | $813M | $3M | $-2M | $-5M | $-39M | $3M | $-499M | $13M | $-43M | $11M | $-788.0K | $12M | $-41M | $11M | $8M | |
| Net Change in Cash | $-2.20B | $1.76B | $62M | $36M | $165M | $106M | $267M | $-297M | $225M | $-8M | $-30M | $91M | $114M | $-144M | $-37M | $142M | |
| Free Cash Flow | · | $200M | · | · | · | $158M | · | · | · | $21M | · | · | · | $-98M | · | · | |
| Levered FCF | · | $193M | · | · | · | · | · | · | · | $18M | · | · | · | $-102M | · | · |
Rentabilidad 7
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.2% | 16.9% | · | -6.0% | 33.6% | 30.0% | · | 15.3% | 16.9% | 13.6% | · | 4.4% | 9.9% | 10.0% | · | -0.48% | |
| Net Margin | 4.5% | 13.8% | · | -4.0% | 29.1% | 24.9% | · | 14.2% | 15.0% | 13.7% | · | 7.0% | 9.4% | 8.5% | · | -1.3% | |
| Pretax Margin | 6.2% | 18.4% | · | -3.4% | 36.1% | 31.9% | · | 18.0% | 18.6% | 16.3% | · | 7.2% | 11.9% | 9.5% | · | -0.38% | |
| EBITDA Margin | 11.2% | 19.1% | · | -6.0% | 33.6% | 33.0% | · | 15.3% | 16.9% | 17.8% | · | 4.4% | 9.9% | 14.4% | · | -0.48% | |
| ROA | 0.47% | 1.3% | · | -0.43% | 3.3% | 2.6% | · | 1.6% | 1.6% | 1.3% | · | 0.62% | 0.88% | 0.81% | · | -0.11% | |
| ROE | 0.72% | 1.8% | · | -0.54% | 4.2% | 3.4% | · | 2.1% | 2.1% | 1.8% | · | 0.85% | 1.2% | 1.1% | · | -0.15% | |
| ROIC | 0.77% | 1.6% | · | -0.90% | 3.7% | 3.0% | · | 1.7% | 1.8% | 1.5% | · | 0.51% | 0.97% | 1.1% | · | -0.18% |
Liquidez y Solvencia 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 5.8 | · | 4.8 | 5.6 | 5.5 | · | 4.3 | 3.1 | 2.7 | · | 2.5 | 4.9 | 4.8 | · | 5.1 | |
| Quick Ratio | 1.2 | 3.9 | · | 2.6 | 3.0 | 2.8 | · | 2.0 | 1.6 | 1.3 | · | 1.2 | 2.2 | 2.0 | · | 2.3 | |
| Debt / Equity | 0.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | 1.8 | 13.5 | · | · | · | · | · | · | · | 24.9 | · | 6.8 | 15.7 | 16.0 | · | -0.5 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.1 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.0 | 0.9 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | 1.1 | 1.2 | · | 1.3 |
Valoración (TTM) 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.36B | $3.11B | · | $3.09B | $3.03B | $2.85B | · | $2.69B | $2.54B | $2.42B | · | $2.28B | $2.23B | $2.15B | · | $1.97B | |
| Net Income TTM | $360M | $501M | · | $502M | $639M | $488M | · | $342M | $292M | $236M | · | $141M | $128M | $193M | · | $105M | |
| Market Cap | $11.07B | $10.92B | · | $10.40B | $10.55B | $13.56B | · | $13.39B | $15.67B | $16.58B | · | $16.66B | $16.31B | $18.24B | · | $15.75B | |
| Enterprise Value | $14.39B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 31.1 | 22.1 | · | 21.1 | 16.8 | 28.2 | · | 39.7 | 54.5 | 71.0 | · | 121.2 | 129.4 | 96.3 | · | 157.0 | |
| P/S | 3.3 | 3.5 | · | 3.4 | 3.5 | 4.8 | · | 5.0 | 6.2 | 6.8 | · | 7.3 | 7.3 | 8.5 | · | 8.0 | |
| P/B | 1.8 | 1.8 | · | 1.7 | 1.8 | 2.3 | · | 2.5 | 3.0 | 3.3 | · | 3.4 | 3.4 | 3.9 | · | 3.4 | |
| P / Tangible Book | 14.1 | 1.9 | · | 1.8 | 1.9 | 2.5 | · | 2.7 | 3.2 | 3.6 | · | 3.8 | 3.8 | 4.4 | · | 3.9 | |
| P / Cash Flow | · | 49.5 | · | · | · | 77.7 | · | · | · | 352.9 | · | · | · | -246.7 | · | · | |
| P / FCF | · | 54.7 | · | · | · | 86.0 | · | · | · | 794.3 | · | · | · | -185.4 | · | · | |
| EV / EBITDA | 129.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 4.3 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 3.2% | 4.5% | · | 4.8% | 6.0% | 3.5% | · | 2.5% | 1.8% | 1.4% | · | 0.83% | 0.77% | 1.0% | · | 0.64% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Margen Operativo % | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% |
| Beneficio neto | $349M | $427M | $168M | $142M | $-64M |
| EPS Diluido | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio corriente | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 |
| Ratio Rápido | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $725M | $487M | $63M | $55M | $209M |
Últimas noticias Noticias recientes que mencionan a esta empresa
- Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years
- ¿Es BioMarin Pharmaceutical Inc. (BMRN) una de las principales acciones baratas para comprar con el mayor potencial de crecimiento?
- BioMarin Nombra a Ian Clark como Presidente de la Junta Directiva
- BioMarin Pharmaceutical (BMRN) informa resultados positivos de los ensayos en curso de VOXZOGO
Señales de trading Señales recientes de compra/venta con precio de entrada y ratio riesgo/recompensa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 616 declarantes · $8.6B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 96 (+2 vs trimestre anterior) | 74 (+9 vs trimestre anterior) | 191 (-17 vs trimestre anterior) | 204 (+39 vs trimestre anterior) | +28.9M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| Dodge & Cox | $849 426 895 | 14 844 930 | 9,87% | Acciones |
| PRIMECAP MANAGEMENT CO/CA/ | $811 962 329 | 14 190 183 | 9,44% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $500 310 680 | 8 743 633 | 5,82% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $494 877 355 | 8 648 678 | 5,75% | Acciones |
| NORGES BANK | $469 659 128 | 8 207 954 | 5,46% | Acciones |
| STATE STREET CORP | $446 370 874 | 7 800 959 | 5,19% | Acciones |
| VIKING GLOBAL INVESTORS LP | $435 819 735 | 7 616 563 | 5,07% | Acciones |
| Vestal Point Capital, LP | $344 750 500 | 6 025 000 | 4,01% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $216 743 752 | 3 787 902 | 2,52% | Acciones |
| Capital Research Global Investors | $200 521 024 | 3 504 387 | 2,33% | Acciones |
| FMR LLC | $196 878 227 | 3 440 724 | 2,29% | Acciones |
| Deep Track Capital, LP | $189 254 063 | 3 307 481 | 2,20% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $180 073 856 | 3 146 120 | 2,09% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $118 549 312 | 2 071 816 | 1,38% | Acciones |
| Assenagon Asset Management S.A. | $100 826 561 | 1 762 086 | 1,17% | Acciones |
| FIRST TRUST ADVISORS LP | $91 910 897 | 1 606 273 | 1,07% | Acciones |
| Jones Hill Capital LP | $81 915 580 | 1 431 590 | 0,95% | Acciones |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $76 264 876 | 1 332 836 | 0,89% | Acciones |
| Swedbank AB | $75 232 112 | 1 314 787 | 0,87% | Acciones |
| DNB Asset Management AS | $72 566 061 | 1 268 194 | 0,84% | Acciones |
| Caisse de depot et placement du Quebec | $70 749 440 | 1 236 446 | 0,82% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $70 030 356 | 1 223 879 | 0,81% | Acciones |
| AMERIPRISE FINANCIAL INC | $65 664 916 | 1 147 544 | 0,76% | Acciones |
| CITADEL ADVISORS LLC | $64 224 186 | 1 122 408 | 0,75% | Acciones |
| Balyasny Asset Management L.P. | $60 344 956 | 1 054 613 | 0,70% | Acciones |
| ARGA Investment Management, LP | $59 474 983 | 1 039 409 | 0,69% | Acciones |
| GOLDMAN SACHS GROUP INC | $56 321 074 | 984 290 | 0,65% | Acciones |
| Brandywine Global Investment Management, LLC | $56 211 687 | 945 847 | 0,65% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $54 484 884 | 952 200 | 0,63% | Opción de compra |
| MACKENZIE FINANCIAL CORP | $53 321 258 | 931 864 | 0,62% | Acciones |
| FRANKLIN RESOURCES INC | $47 889 936 | 836 944 | 0,56% | Acciones |
| Hudson Bay Capital Management LP | $47 206 500 | 825 000 | 0,55% | Acciones |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $40 949 264 | 715 646 | 0,48% | Acciones |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $39 869 980 | 696 784 | 0,46% | Acciones |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $39 311 857 | 687 030 | 0,46% | Acciones |
| Palo Alto Investors LP | $39 068 500 | 682 777 | 0,45% | Acciones |
| Defilade Capital Management, L.P. | $39 024 326 | 682 005 | 0,45% | Acciones |
| Qube Research & Technologies Ltd | $38 270 739 | 668 835 | 0,44% | Acciones |
| Eagle Health Investments LP | $35 743 961 | 624 676 | 0,42% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $34 419 661 | 601 532 | 0,40% | Acciones |
| BOONE CAPITAL MANAGEMENT LLC | $33 371 791 | 583 219 | 0,39% | Acciones |
| Camber Capital Management LP | $32 982 000 | 600 000 | 0,38% | Acciones |
| River Road Asset Management, LLC | $31 069 888 | 542 990 | 0,36% | Acciones |
| RHUMBLINE ADVISERS | $29 570 438 | 516 786 | 0,34% | Acciones |
| Trails Edge Capital Partners, LP | $29 296 640 | 512 000 | 0,34% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $28 048 615 | 490 189 | 0,33% | Acciones |
| Jefferies Financial Group Inc. | $26 679 283 | 466 258 | 0,31% | Acciones |
| LOOMIS SAYLES & CO L P | $25 986 177 | 454 145 | 0,30% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $25 856 059 | 451 871 | 0,30% | Acciones |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $25 588 784 | 447 200 | 0,30% | Acciones |
| California Public Employees Retirement System | $25 124 959 | 439 094 | 0,29% | Acciones |
| Rockefeller Capital Management L.P. | $24 797 775 | 433 376 | 0,29% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24 038 122 | 420 100 | 0,28% | Opción de venta |
| SEB Asset Management AB | $23 583 178 | 412 150 | 0,27% | Acciones |
| Robeco Institutional Asset Management B.V. | $23 358 064 | 408 215 | 0,27% | Acciones |
| Pictet Asset Management Holding SA | $22 789 414 | 395 382 | 0,26% | Acciones |
| BlackRock, Inc. | $22 697 229 | 396 666 | 0,26% | Acciones |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $22 513 495 | 393 455 | 0,26% | Acciones |
| PRUDENTIAL FINANCIAL INC | $22 325 585 | 390 171 | 0,26% | Acciones |
| Soleus Capital Management, L.P. | $21 490 230 | 375 572 | 0,25% | Acciones |
| Freestone Grove Partners LP | $20 839 181 | 364 194 | 0,24% | Acciones |
| Sofinnova Investments, Inc. | $20 517 261 | 358 568 | 0,24% | Acciones |
| Swiss National Bank | $20 427 540 | 357 000 | 0,24% | Acciones |
| LAZARD ASSET MANAGEMENT LLC | $20 049 716 | 350 397 | 0,23% | Acciones |
| BANK OF AMERICA CORP /DE/ | $19 371 831 | 338 550 | 0,23% | Acciones |
| EASTERLY INVESTMENT PARTNERS LLC | $18 847 524 | 329 387 | 0,22% | Acciones |
| SPHERA FUNDS MANAGEMENT LTD. | $18 799 631 | 328 550 | 0,22% | Acciones |
| DIADEMA PARTNERS LP | $17 901 048 | 312 846 | 0,21% | Acciones |
| SECTOR GAMMA AS | $16 875 208 | 294 918 | 0,20% | Acciones |
| Rhenman & Partners Asset Management AB | $16 622 410 | 290 500 | 0,19% | Acciones |
| Walleye Capital LLC | $16 492 692 | 288 233 | 0,19% | Acciones |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $16 114 296 | 281 620 | 0,19% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $16 009 266 | 283 400 | 0,19% | Acciones |
| Bridgewater Associates, LP | $15 730 407 | 274 911 | 0,18% | Acciones |
| Susquehanna Portfolio Strategies, LLC | $15 653 218 | 273 562 | 0,18% | Acciones |
| Redmile Group, LLC | $15 172 970 | 265 169 | 0,18% | Acciones |
| Amundi | $14 864 727 | 259 782 | 0,17% | Acciones |
| Eversept Partners, LP | $14 282 513 | 249 607 | 0,17% | Acciones |
| Distillate Capital Partners LLC | $14 242 974 | 248 916 | 0,17% | Acciones |
| RICE HALL JAMES & ASSOCIATES, LLC | $14 203 377 | 248 224 | 0,17% | Acciones |
| CAPITAL FUND MANAGEMENT S.A. | $13 470 789 | 235 421 | 0,16% | Acciones |
| CITADEL ADVISORS LLC | $13 189 210 | 230 500 | 0,15% | Opción de compra |
| CANADA PENSION PLAN INVESTMENT BOARD | $12 868 778 | 224 900 | 0,15% | Acciones |
| M&G PLC | $12 317 472 | 216 096 | 0,14% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12 137 385 | 214 859 | 0,14% | Acciones |
| GLENMEDE TRUST CO NA | $11 782 055 | 205 908 | 0,14% | Acciones |
| Retirement Systems of Alabama | $11 438 907 | 199 911 | 0,13% | Acciones |
| IEQ CAPITAL, LLC | $11 328 874 | 197 988 | 0,13% | Acciones |
| Mariner, LLC | $11 021 160 | 192 607 | 0,13% | Acciones |
| Monaco Asset Management SAM | $10 582 095 | 184 937 | 0,12% | Acciones |
| Engineers Gate Manager LP | $10 393 841 | 181 647 | 0,12% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $9 840 867 | 171 983 | 0,11% | Acciones |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $9 713 000 | 169 746 | 0,11% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $9 595 050 | 167 687 | 0,11% | Acciones |
| VAN ECK ASSOCIATES CORP | $9 444 504 | 165 056 | 0,11% | Acciones |
| PEREGRINE CAPITAL MANAGEMENT LLC | $9 310 495 | 162 714 | 0,11% | Acciones |
| CWM, LLC | $9 018 745 | 159 652 | 0,10% | Acciones |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $9 015 469 | 157 558 | 0,10% | Acciones |
| BARCLAYS PLC | $8 865 839 | 154 943 | 0,10% | Acciones |
| Legal & General Group Plc | $8 722 675 | 152 441 | 0,10% | Acciones |
Informantes de la empresa 48 insiders · 19 directivos · 29 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Alexander Hardy | Chief Executive Officer | 17 de marzo de 2025 A | 175 583 | 0 | 0 | $0 |
| Louis Drapeau | Chief Executive Officer | 2 de mayo de 2005 A | 14 934 | 0 | 0 | $0 |
| Fredric D Price | Chief Executive Officer | 6 de mayo de 2004 P | 79 285 | 0 | 0 | $0 |
| Brian Mueller | EVP, Chief Financial Officer | 17 de marzo de 2025 A | 99 781 | 0 | 0 | $0 |
| Daniel K Spiegelman | EVP, Chief Financial Officer | 22 de junio de 2018 S | 51 070 | 0 | 0 | $0 |
| Jeffrey H Cooper | SVP, Chief Financial Officer | 14 de mayo de 2012 M | 41 089 | 0 | 0 | $0 |
| Henry J Fuchs | President, Worldwide R&D | 13 de septiembre de 2024 F | 185 074 | 0 | 0 | $0 |
| Cristin Hubbard | EVP, Chief Commercial Officer | 20 de mayo de 2025 F | 30 545 | 0 | 0 | $0 |
| Erin Burkhart | GVP, Chief Accounting Officer | 20 de mayo de 2025 S | 14 173 | 0 | 0 | $0 |
| Gregory R Friberg | EVP, Chief R&D Officer | 17 de marzo de 2025 A | 46 810 | 0 | 0 | $0 |
| Charles Greg Guyer | EVP, Chief Technical Officer | 17 de marzo de 2025 A | 80 838 | 0 | 0 | $0 |
| George Eric Davis | EVP, Chief Legal Officer | 17 de marzo de 2025 A | 82 915 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | 2 de mayo de 2024 S | 66 767 | 0 | 0 | $0 |
| Robert Baffi | EVP, Technical Operations | 22 de junio de 2018 M | 83 276 | 0 | 0 | $0 |
| Steve Aselage | EVP, Chief Business Officer | 2 de julio de 2012 M | 59 030 | 0 | 0 | $0 |
| Emil D Kakkis | Chief Medical Officer | 2 de marzo de 2009 M | 39 621 | 0 | 0 | $0 |
| Stuart J Swiedler | SVP, Clinical Affairs | 7 de julio de 2008 A | 12 000 | 0 | 0 | $0 |
| Christopher M Starr | SVP, Chief Scientific Officer | 1 de diciembre de 2005 M | 295 176 | 0 | 0 | $0 |
| Jeffrey Landau | SVP, Administration | 31 de octubre de 2004 A | 2 740 | 0 | 0 | $0 |
| Elizabeth M Anderson | Consejero | 2 de junio de 2026 A | 41 940 | 0 | 0 | $0 |
| Barbara W. Bodem | Consejero | 2 de junio de 2026 A | 21 045 | 0 | 0 | $0 |
| Maykin Ho | Consejero | 2 de junio de 2026 A | 35 500 | 0 | 0 | $0 |
| Mark J Enyedy | Consejero | 2 de junio de 2026 A | 21 040 | 0 | 0 | $0 |
| Athena Countouriotis | Consejero | 2 de junio de 2026 A | 21 040 | 0 | 0 | $0 |
| Robert J. Hombach | Consejero | 2 de junio de 2026 A | 49 360 | 0 | 0 | $0 |
| Timothy P Walbert | Consejero | 2 de junio de 2026 A | 17 270 | 0 | 0 | $0 |
| Ian T Clark | Consejero | 2 de junio de 2026 A | 14 490 | 0 | 0 | $0 |
| Willard H Dere | Consejero | 2 de junio de 2026 A | 46 440 | 0 | 0 | $0 |
| Richard A Meier | Consejero | 20 de mayo de 2025 A | 127 426 | 0 | 0 | $0 |
| Elaine J Heron | Consejero | 3 de junio de 2024 M | 97 720 | 0 | 0 | $0 |
| David E I Pyott | Consejero | 21 de mayo de 2024 A | 49 750 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Consejero | 20 de mayo de 2024 F | 473 792 | 0 | 0 | $0 |
| Dennis Slamon | Consejero | 18 de marzo de 2024 M | 31 299 | 0 | 0 | $0 |
| Mark J Alles | Consejero | 23 de mayo de 2023 A | 15 095 | 0 | 0 | $0 |
| Bryan V Lawlis | Consejero | 23 de mayo de 2023 A | 33 140 | 0 | 0 | $0 |
| Michael G Grey | Consejero | 5 de junio de 2018 A | 34 110 | 0 | 0 | $0 |
| Alan Lewis | Consejero | 5 de junio de 2018 A | 25 360 | 0 | 0 | $0 |
| Kathryn E Falberg | Consejero | 15 de julio de 2016 A | 2 640 | 0 | 0 | $0 |
| William D Young | Consejero | 10 de junio de 2015 A | 11 875 | 0 | 0 | $0 |
| Kenneth Bate | Consejero | 10 de junio de 2015 A | 11 875 | 0 | 0 | $0 |
| Pierre Lapalme | Consejero | 10 de junio de 2015 A | 31 250 | 0 | 0 | $0 |
| Joseph Klein III | Consejero | 8 de marzo de 2010 S | 35 000 | 0 | 0 | $0 |
| Franz L Cristiani | Consejero | 14 de junio de 2006 A | — | 0 | 0 | $0 |
| Erich Sager | Consejero | 24 de febrero de 2006 M | 3 309 | 0 | 0 | $0 |
| Gwynn Williams | Consejero | 30 de noviembre de 2004 A | 812 565 | 0 | 0 | $0 |
| John Urquhart | Consejero | 28 de julio de 2004 A | — | 0 | 0 | $0 |
| BIOMARIN PHARMACEUTICAL INC | Propietario del 10% | 8 de diciembre de 2012 J | 6 666 667 | 0 | 0 | $0 |
| Mark Wood | — | 22 de mayo de 2013 M | 20 277 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 4 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc., BioMarin Falcons B.V., BioMarin Giants B.V. ×5 presentaciones | 2 de febrero de 2015 | — | Presentación inicial | — | SEC |
| Millenco LLC, Integrated Core Strategies (US) LLC, Catapult Partners, Ltd., Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC, Israel A. Englander ×2 presentaciones | 31 de julio de 2009 | — | Presentación inicial | — | SEC |
| 6 de junio de 2005 | — | Presentación inicial | — | SEC | |
| OrbiMed Advisors LLC, OrbiMed Capital LLC, Samuel D. Isaly, Richard B. Brewer, Joseph Klein, III ×2 presentaciones | 6 de mayo de 2005 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 110 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| GNOM · Global X Funds | 4,09% | 39 792 NS | 31 de mayo de 2026 | N-PORT |
| PBE · Invesco Exchange-Traded Fund Trust | 2,89% | 164 036 SH | 8 de agosto de 2026 | Diario |
| BBP · ETFis Series Trust I | 1,61% | 17 750 NS | 30 de abril de 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,27% | 12 555 NS | 30 de abril de 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,14% | 40 919 NS | 30 de abril de 2026 | N-PORT |
| RNIN · EA Series Trust | 1,12% | 31 743 NS | 30 de abril de 2026 | N-PORT |
| IBB · iShares Trust | 0,90% | 1 397 505 SH | 8 de agosto de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,84% | 10 516 SH | 8 de agosto de 2026 | Diario |
| LABU · Direxion Shares ETF Trust | 0,84% | 80 485 NS | 30 de abril de 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,83% | 133 988 NS | 30 de abril de 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,69% | 1 977 NS | 30 de abril de 2026 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 0,64% | 18 230 NS | 31 de mayo de 2026 | N-PORT |
| SMMV · iShares Trust | 0,63% | 29 931 SH | 8 de agosto de 2026 | Diario |
| BIB · ProShares Trust | 0,55% | 7 110 NS | 31 de mayo de 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,54% | 3 021 NS | 31 de mayo de 2026 | N-PORT |
| ABCS · EA Series Trust | 0,48% | 948 NS | 29 de mayo de 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,44% | 259 NS | 29 de mayo de 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,43% | 24 857 NS | 30 de abril de 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,38% | 26 083 SH | 8 de agosto de 2026 | Diario |
| XJH · iShares Trust | 0,37% | 26 156 SH | 8 de agosto de 2026 | Diario |
| IJK · iShares Trust | 0,36% | 643 881 SH | 8 de agosto de 2026 | Diario |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 108 709 SH | 8 de agosto de 2026 | Diario |
| IJH · iShares Trust | 0,33% | 6 668 981 SH | 8 de agosto de 2026 | Diario |
| PTMC · Pacer Funds Trust | 0,30% | 22 042 NS | 30 de abril de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,30% | 2 559 860 SH | 8 de agosto de 2026 | Diario |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,30% | 312 378 SH | 8 de agosto de 2026 | Diario |
| IJJ · iShares Trust | 0,29% | 422 817 SH | 8 de agosto de 2026 | Diario |
| DFSV · Dimensional ETF Trust | 0,29% | 400 897 NS | 30 de abril de 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,28% | 31 691 NS | 30 de abril de 2026 | N-PORT |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,27% | 71 381 SH | 8 de agosto de 2026 | Diario |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,25% | 24 275 NS | 30 de abril de 2026 | N-PORT |
| ISCV · iShares Trust | 0,24% | 27 744 SH | 8 de agosto de 2026 | Diario |
| MVV · ProShares Trust | 0,24% | 6 639 NS | 31 de mayo de 2026 | N-PORT |
| JIII · Janus Detroit Street Trust | 0,22% | 6 823 NS | 30 de abril de 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,21% | 3 182 NS | 30 de abril de 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,21% | 77 243 NS | 30 de abril de 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,20% | 518 955 NS | 31 de mayo de 2026 | N-PORT |
| IYH · iShares Trust | 0,19% | 114 684 SH | 8 de agosto de 2026 | Diario |
| ISCB · iShares Trust | 0,18% | 8 611 SH | 8 de agosto de 2026 | Diario |
| UMDD · ProShares Trust | 0,17% | 927 NS | 31 de mayo de 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,16% | 19 998 SH | 8 de agosto de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,16% | 84 082 NS | 30 de abril de 2026 | N-PORT |
| FNDA · SCHWAB STRATEGIC TRUST | 0,16% | 245 186 NS | 31 de mayo de 2026 | N-PORT |
| SMMD · iShares Trust | 0,16% | 95 606 SH | 8 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,15% | 534 462 SH | 8 de agosto de 2026 | Diario |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,15% | 31 223 SH | 8 de agosto de 2026 | Diario |
| VFVA · VANGUARD WELLINGTON FUND | 0,14% | 20 990 SH | 8 de agosto de 2026 | Diario |
| DFAS · Dimensional ETF Trust | 0,14% | 361 639 NS | 30 de abril de 2026 | N-PORT |
| ISCG · iShares Trust | 0,13% | 21 146 SH | 8 de agosto de 2026 | Diario |
| VB · VANGUARD INDEX FUNDS | 0,13% | 4 433 137 SH | 8 de agosto de 2026 | Diario |